Physician profile
Nancy K Williams
NPI 1245234061
$1,443.28
in general payments reported to CMS, 2019-2025
15 companies · $198 in 2025
The $198 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $202 · 2020: $73.12 · 2021: $189 · 2022: $234 · 2023: $335 · 2024: $212 · 2025: $198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $745.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $745.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $527.95 | 2021-2025 | Qulipta, Ubrelvy |
| Novo Nordisk INC | $320.15 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Merck Sharp & Dohme LLC | $102.52 | 2019-2021 | |
| Glaxosmithkline, LLC. | $90.92 | 2022-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $90.37 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Allergan, INC. | $72.43 | 2019-2020 | |
| Esperion Therapeutics, INC. | $41.18 | 2021 | |
| Pfizer INC. | $37.10 | 2019 | |
| Novartis Pharmaceuticals Corporation | $33.44 | 2019-2023 | |
| Chiesi USA, INC. | $27.80 | 2024 | Elfabrio |
| Lilly USA, LLC | $26.20 | 2019-2023 | Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.52 | 2022 | |
| Sumitomo Pharma America, INC. | $22.71 | 2025 | Gemtesa |
| Idorsia Pharmaceuticals US INC | $13.14 | 2023 | Quviviq |
| Biohaven Pharmaceuticals, INC. | $12.85 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.